FDA approved fillers
TEOXANE announces FDA approval for three HA dermal fillers indicated for dynamic facial wrinkles and folds
TEOXANE Laboratories, a global leader in hyaluronic acid dermal fillers, have announced that they have received US Food and Drug Administration (FDA) approval for three HA dermal fillers— RHA2, RHA3 and RHA4— for the correction of moderate to severe dynamic facial wrinkles and folds in adults aged 22 years or older.
The first hyaluronic acid that respects facial expressiveness, the RHA range was created according to a patented process, making it possible to meet the specific requirements of mobile facial areas.
Teoxane’s Founder and CEO Mrs Valerie Taupin said: “Since its inception in 2003, the foundations of the company have been based on integrated research and development. Today we are delighted with the news of the FDA approval of RHA2, RHA3 and RHA4 for sale in the US market. This further reinforces our commitment to delivering science-based, highquality HA dermal fillers to the global market”.
This news will help to further strengthen the positioning of Teoxane as a world class HA provider in today’s aesthetic market.